Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team.

J Clin Oncol. 2020 Jan 20;38(3):257-270. doi: 10.1200/JCO.19.01053. Epub 2019 Dec 3.

PMID:
31794324
2.

Teaming up for CAR-T cell therapy.

Wäsch R, Munder M, Marks R.

Haematologica. 2019 Dec;104(12):2335-2336. doi: 10.3324/haematol.2019.228676. No abstract available.

3.

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2020 Apr;61(4):875-886. doi: 10.1080/10428194.2019.1695051. Epub 2019 Nov 28.

PMID:
31779510
4.

Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?

Engelhardt M, Yong K, Bringhen S, Wäsch R.

Haematologica. 2019 Nov;104(11):2128-2131. doi: 10.3324/haematol.2019.228684. No abstract available.

5.

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.

Kotrova M, Volland A, Kehden B, Trautmann H, Ritgen M, Wäsch R, Faul C, Viardot A, Schwartz S, Baldus CD, Gökbuget N, Brüggemann M.

Leukemia. 2019 Oct 22. doi: 10.1038/s41375-019-0599-1. [Epub ahead of print] No abstract available.

PMID:
31641191
6.

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Kovacs SB, Luan J, Dold SM, Weis A, Pantic M, Duyster J, Wäsch R, Engelhardt M.

Haematologica. 2020 Mar;105(3):e138-e140. doi: 10.3324/haematol.2019.232330. Epub 2019 Aug 29. No abstract available.

7.

PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.

Müller TA, Pennisi S, Zwick A, Decker S, Klein C, Rister B, Rudorf A, Kissel S, Follo M, Wäsch R, Illert AL, Pfeifer D, Oostendorp R, Waskow C, Dierks C, Duyster J.

Leukemia. 2019 May;33(5):1296-1301. doi: 10.1038/s41375-019-0428-6. Epub 2019 Feb 28. No abstract available.

PMID:
30816332
8.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Jul;286(1):63-74. doi: 10.1111/joim.12882. Epub 2019 Apr 8.

9.

APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells.

Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, Felthaus J, Schüler J, Duyster J, Illert AL, Engelhardt M, Wäsch R.

Cell Mol Life Sci. 2019 Jan;76(2):369-380. doi: 10.1007/s00018-018-2952-3. Epub 2018 Oct 24.

PMID:
30357422
10.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

11.

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Schmidts A, Grünewald J, Kleber M, Terpos E, Ihorst G, Reinhardt H, Walz G, Wäsch R, Engelhardt M, Zschiedrich S.

Clin Exp Nephrol. 2019 Feb;23(2):199-206. doi: 10.1007/s10157-018-1626-7. Epub 2018 Aug 20.

PMID:
30128942
12.

Carfilzomib.

Engelhardt M, Szymaniak-Vits M, Ajayi S, Dold SM, Müller SJ, Scheubeck S, Wäsch R.

Recent Results Cancer Res. 2018;212:265-283. doi: 10.1007/978-3-319-91439-8_13.

PMID:
30069635
13.

Pomalidomide.

Engelhardt M, Ajayi S, Reinhardt H, Müller SJ, Dold SM, Wäsch R.

Recent Results Cancer Res. 2018;212:169-185. doi: 10.1007/978-3-319-91439-8_8.

PMID:
30069630
14.

Ruxolitinib.

Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R.

Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6.

PMID:
30069628
15.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
16.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension.

Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26. Review.

17.

Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning.

Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, Marks R, Prasse A.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2277-2284. doi: 10.1016/j.bbmt.2018.06.024. Epub 2018 Jun 28.

18.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

19.

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, Knop S, Wasch R.

Haematologica. 2018 May;103(5):755-758. doi: 10.3324/haematol.2018.188516. No abstract available.

20.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

21.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
22.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>.

Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Köhler M, Einsele H, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2018 Nov;59(11):2692-2699. doi: 10.1080/10428194.2018.1448084. Epub 2018 Mar 23. No abstract available.

PMID:
29569975
23.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

24.

Current developments in immunotherapy in the treatment of multiple myeloma.

Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M.

Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6. Review.

25.

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.

Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obländer J, Pressler J, Böhm V, Brüggemann M, Wunderle L, Hüttmann A, Wäsch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D.

Blood. 2018 Mar 29;131(13):1464-1475. doi: 10.1182/blood-2017-07-796862. Epub 2018 Jan 18.

PMID:
29348129
26.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.

Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P.

Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review.

27.

Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.

Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kühbach K, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30. No abstract available.

PMID:
29081261
28.

Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature.

Rassner MP, Seidl M, Salzer U, Rajkumar SV, Epting T, Wäsch R, Neumann-Haefelin E, Engelhardt M.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e1-e7. doi: 10.1016/j.clml.2017.09.019. Epub 2017 Oct 3. No abstract available.

PMID:
29066226
29.

The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.

Greil C, Ihorst G, Gaiser F, Salzer U, Bisse E, Kastritis E, Ludwig H, Wäsch R, Engelhardt M.

Eur J Haematol. 2017 Nov;99(5):449-458. doi: 10.1111/ejh.12958. Epub 2017 Oct 5.

PMID:
28886228
30.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688
31.

Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.

Kobitzsch B, Gökbuget N, Schwartz S, Reinhardt R, Brüggemann M, Viardot A, Wäsch R, Starck M, Thiel E, Hoelzer D, Burmeister T.

Haematologica. 2017 Oct;102(10):1739-1747. doi: 10.3324/haematol.2016.161273. Epub 2017 Jul 27.

32.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
33.

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.

Schnerch D, Schüler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2017 Mar 28;8(13):21153-21166. doi: 10.18632/oncotarget.15503.

34.

[Multidisciplinary Tumor Boards: Facts and Satisfaction Analysis of an Indispensable Comprehensive Cancer Center Instrument].

Engelhardt M, Selder R, Pandurevic M, Möller M, Ihorst G, Waldschmidt J, Herget G, Wäsch R.

Dtsch Med Wochenschr. 2017 May;142(9):e51-e60. doi: 10.1055/s-0043-100054. Epub 2017 Feb 27. German.

PMID:
28241373
35.

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.

Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, Müller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, Wäsch R.

Haematologica. 2017 May;102(5):910-921. doi: 10.3324/haematol.2016.162693. Epub 2017 Feb 2.

36.

Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.

Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2017 Aug;58(8):1849-1858. doi: 10.1080/10428194.2016.1271946. Epub 2017 Jan 13.

PMID:
28084849
37.

Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?

Engelhardt M, Ihorst G, Caers J, Günther A, Wäsch R.

Haematologica. 2016 Nov;101(11):1276-1278. No abstract available.

38.

Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ⩾60 years with advanced AML/MDS.

Bertz H, Lübbert M, Ohneberg K, Zeiser R, Wäsch R, Marks R, Finke J.

Leukemia. 2016 Dec;30(12):2426-2429. doi: 10.1038/leu.2016.248. Epub 2016 Aug 30. No abstract available.

PMID:
27573558
39.

Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Engelhardt M, Dold SM, Ihorst G, Zober A, Möller M, Reinhardt H, Hieke S, Schumacher M, Wäsch R.

Haematologica. 2016 Sep;101(9):1110-9. doi: 10.3324/haematol.2016.148189. Epub 2016 Jun 16.

40.

Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia.

Ewerth D, Schmidts A, Hein M, Schnerch D, Kvainickas A, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2016 Jul 26;7(30):48220-48230. doi: 10.18632/oncotarget.10196.

41.

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M.

Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26. Review.

42.

Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation.

Finke J, Schmoor C, Bertz H, Marks R, Wäsch R, Zeiser R, Hackanson B.

Bone Marrow Transplant. 2016 Jun;51(6):771-7. doi: 10.1038/bmt.2015.338. Epub 2016 Jan 11.

PMID:
26752137
43.

From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.

Lorenz J, Waldschmidt J, Wider D, Follo M, Ihorst G, Chatterjee M, May AM, Duyster J, Rosenwald A, Wäsch R, Zirlik K, Engelhardt M.

Br J Haematol. 2016 Sep;174(6):985-9. doi: 10.1111/bjh.13825. Epub 2015 Oct 22. No abstract available.

PMID:
26491948
44.

The role of APC/C(Cdh1) in replication stress and origin of genomic instability.

Greil C, Krohs J, Schnerch D, Follo M, Felthaus J, Engelhardt M, Wäsch R.

Oncogene. 2016 Jun 9;35(23):3062-70. doi: 10.1038/onc.2015.367. Epub 2015 Oct 12.

PMID:
26455319
45.

The Use of SNAP Labeling to Study Cell Cycle Oscillatory Proteins.

Greil C, Follo M, Engelhardt M, Wäsch R.

Methods Mol Biol. 2016;1342:201-8. doi: 10.1007/978-1-4939-2957-3_11.

PMID:
26254925
46.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

47.

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.

Engelhardt M, Ihorst G, Landgren O, Pantic M, Reinhardt H, Waldschmidt J, May AM, Schumacher M, Kleber M, Wäsch R.

Haematologica. 2015 Oct;100(10):1340-9. doi: 10.3324/haematol.2015.127548. Epub 2015 Jul 9.

48.

Analysis of survival by tumor response: have we learnt any better?

Ihorst G, Waldschmidt J, Schumacher M, Wäsch R, Engelhardt M.

Ann Hematol. 2015 Sep;94(9):1615-6. doi: 10.1007/s00277-015-2426-8. Epub 2015 Jun 24. Review. No abstract available.

PMID:
26099841
49.

Trained clinical nurse specialists proficiently obtain bone marrow aspirates and trephine biopsies in a nearly painless procedure--a prospective evaluation study.

Naegele M, Leppla L, Kiote-Schmidt C, Ihorst G, Rebafka A, Koller A, May AM, Hasemann M, Duyster J, Wäsch R, Engelhardt M.

Ann Hematol. 2015 Sep;94(9):1577-84. doi: 10.1007/s00277-015-2405-0. Epub 2015 Jun 2.

PMID:
26027858
50.

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.

Supplemental Content

Support Center